Delhi’s Drugs Control Department has seized 2,104 units of insulin preparations worth ₹20,06,024 during a special inspection of wholesale drug markets, uncovering violations of storage and labeling laws at four firms. The operation, conducted to ensure the availability of safe and effective medicines, targeted insulin preparations that require strict cold chain maintenance.

Insulin Stock Found with Defaced Labels and Improper Storage

During the inspection of six wholesale drug firms, four were found to be in violation of the Drugs and Cosmetics Act, 1940, and the Drugs Rules, 1945. The seized insulin preparations included Tresiba FlexTouch 100U/ml Pen, Glaritus 100U/ml Cartridges, Humalog Mix50 KwikPen 100U/ml, Apidra SoloStar 100U/ml, and Toujeo SoloStar 300U/ml.

These products were found to have defaced inscriptions on labels meant for government or institutional supply, and two of the firms were storing insulin at normal room temperature, violating the required cold chain conditions. The firms also failed to produce valid purchase records for the stock.

Strict Regulatory Measures and Legal Action Taken

Delhi Health Minister Pankaj Kumar Singh stated that ensuring the availability of safe and effective medicines is a top priority. He emphasized the government’s commitment to maintaining strict regulatory oversight under the leadership of Chief Minister Smt. Rekha Gupta.

Following the inspection, two firms have been booked for violations under the relevant provisions of the Drugs and Cosmetics Act, 1940, and the Drugs Rules, 1945. Drug samples have also been collected and sent for testing and analysis to verify their quality and compliance with standards.

The Delhi Drugs Control Department reiterated its commitment to safeguarding public health and ensuring compliance with statutory provisions related to the storage and distribution of life-saving medicines.

Impact on Public Health and Regulatory Compliance

The seizure of these insulin preparations has significant implications for public health, as insulin is a critical medication for patients with diabetes. Improper storage and labeling could lead to compromised efficacy or safety of the drugs.

According to health experts, the cold chain maintenance is essential for preserving the integrity of insulin products. Failure to comply with these conditions could result in the degradation of the medication, posing serious health risks to patients.

Delhi’s enforcement drive highlights the importance of regulatory compliance in the pharmaceutical sector. Similar inspections have been conducted in the past, but this is one of the largest seizures of insulin stock in the region.

The Delhi Drugs Control Department has not disclosed the names of the firms involved, but officials said the action is part of a broader effort to ensure the availability of quality medicines and prevent the distribution of substandard or mislabeled drugs.

With the rising prevalence of diabetes in India, ensuring the availability of safe and effective insulin is crucial. According to the World Health Organization, India is home to the world’s largest population of diabetic patients, with over 74 million people affected as of 2021.

As the investigation continues, the Delhi government has reiterated its commitment to maintaining strict regulatory oversight and taking strict action against any violations involving life-saving medicines.